Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients
November 20th 2024
Douglas Sborov, MD, discusses how key factors, such as patient eligibility for ASCT, decision-making processes for patients with transplant-eligible NDMM, and the influence of depth of response, including MRD negativity, shape frontline therapy strategies.